Search Results - "Swensen, Ron"

Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer by Liao, John B., Jejurikar, Nikita S., Hitchcock-Bernhardt, Katie M., Gwin, William R., Reichow, Jessica L., Dang, Yushe, Childs, Jennifer S., Coveler, Andrew L., Swensen, Ron E., Goff, Barbara A., Disis, Mary L., Salazar, Lupe G.

“…Denileukin diftitox (ONTAK) is a diphtheria/IL-2R fusion protein able to deplete regulatory T cells in peripheral blood. Regulatory T cells in the local immune…”
Get full text

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates by Liao, John B, Gwin, William R, Urban, Renata R, Hitchcock-Bernhardt, Katie M, Coveler, Andrew L, Higgins, Doreen M, Childs, Jennifer S, Shakalia, Hania N, Swensen, Ron E, Stanton, Sasha E, Tinker, Anna V, Wahl, Tanya A, Ancheta, Richard G, McGonigle, Kathryn F, Dai, James Y, Disis, Mary L, Goff, Barbara A

“…BackgroundAnti-programmed death 1 (PD1)/programmed cell death ligand 1 (PD-L1) therapies have shown modest activity as monotherapy in recurrent ovarian cancer…”
Get full text

Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer by GOODELL, Vivian, SALAZAR, Lupe G, URBAN, Nicole, DRESCHER, Charles W, GRAY, Heidi, SWENSEN, Ron E, MCLNTOSH, Martin W, DISIS, Mary L

“…Presence of intratumoral T-cell infiltration has been linked to improved survival in ovarian cancer patients. We questioned whether antibody immunity specific…”
Get full text

Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer by Liao, John B, Swensen, Ron E, Ovenell, Kelsie J, Hitchcock-Bernhardt, Katie M, Reichow, Jessica L, Apodaca, Minjun C, D'Amico, Leonard, Childs, Jennifer S, Higgins, Doreen M, Buening, Barbara J, Goff, Barbara A, Disis, Mary L

“…Abstract Background Granulocyte macrophage colony-stimulating factor (GM-CSF) stimulates immunity via recruitment of antigen presenting cells and tumor…”
Get full text

Implementing the "Flipped Classroom" on a Gynecologic Oncology Service by Urban, Renata R, Swensen, Ron E, Schulkin, Jay, Schiff, Melissa A

“…To determine the impact of a new cur- riculum based on the "flipped classroom" model on the gynecologic oncology (gyn onc) section of the annual in-service…”
Get full text

Pelvic exenteration in the age of modern chemoradiation by McLean, Kate A, Zhang, Weiya, Dunsmoor-Su, Rebecca F, Shah, Chirag A, Gray, Heidi J, Swensen, Ron E, Goff, Barbara A

“…Abstract Background To examine outcomes after pelvic exenteration in women treated with modern chemoradiation and surgical techniques. Methods All patients at…”
Get full text

Suicide in women with gynecologic cancer by Mahdi, Haider, Swensen, Ron E, Munkarah, Adnan R, Chiang, Seine, Luhrs, Kayla, Lockhart, David, Kumar, Sanjeev

“…Abstract Objective(s) To characterize the suicide rates among patients with gynecologic cancer in the Unites States and to identify factors associated with…”
Get full text

Ovarian cancer in the elderly: Outcomes with neoadjuvant chemotherapy or primary cytoreduction by McLean, Kate A, Shah, Chirag A, Thompson, Sara A, Gray, Heidi J, Swensen, Ron E, Goff, Barbara A

“…Abstract Background Recent studies have suggested inferior outcomes for elderly women with ovarian cancer. Our goal was to evaluate neoadjuvant chemotherapy…”
Get full text

FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence by Press, Joshua Z, Allison, Kimberly H, Garcia, Rochelle, Everett, Elise N, Pizer, Ellen, Swensen, Ron E, Tamimi, Hisham K, Gray, Heidi J, Peters, William A, Goff, Barbara A

“…Abstract Objective. To characterize clinical features of vulvar Paget's disease, and examine the quantity of immunosuppressive regulatory T-cells in vulvar…”
Get full text

Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer by Gray, Heidi J, Shah, Chirag A, Swensen, Ron E, Tamimi, Hisham K, Goff, Barbara A

“…Abstract Objective GOG 172 showed a survival benefit with intraperitoneal (IP) cisplatin for advanced ovarian cancer, but patients tolerated the regimen…”
Get full text

Disparities in treatment and survival between African American and White women with vaginal cancer by Mahdi, Haider, Kumar, Sanjeev, Hanna, Rabbie K, Munkarah, Adnan R, Lockhart, David, Morris, Robert T, Tamimi, Hisham, Swensen, Ron E, Doherty, Mark

“…Abstract Objective The study aims to compare the difference in treatment and survival between White (W) and African American (AA) patients with vaginal cancer…”
Get full text

An evaluation of cervical cancer in women age sixty and over by Fox, Katrina V, Shah, Chirag A, Swisher, Elizabeth M, Garcia, Rochelle L, Mandel, Lynn S, Gray, Heidi J, Swensen, Ron E, Goff, Barbara A

“…Abstract Objective To assess prior cervical cancer screening, stage at time of diagnosis and outcome in women sixty years of age and over with cervical cancer…”
Get full text

Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: A phase I trial of the Puget Sound Oncology Consortium by Swisher, Elizabeth M., Swensen, Ron E., Greer, Benjamin, Tamimi, Hisham, Goff, Barbara A., Garcia, Rochelle, Koh, Wui-jin

“…Define the maximum tolerated dose of weekly gemcitabine given concomitantly with standard weekly cisplatin and pelvic radiotherapy for primary treatment of…”
Get full text

Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers by Salazar, Lupe G, Coveler, Andrew L, Swensen, Ron E, Gooley, Theodore A, Goodell, Vivian, Schiffman, Kathy, Disis, Mary L

“…Abstract The ability of a cancer vaccine to elicit a specific measurable T-cell response is increasingly being used to prioritize immunization strategies for…”
Get full text

Surgery for ovarian cancer: rationale and guidelines by Greer, Benjamin E, Swensen, Ron E, Gray, Heidi J

“…Ovarian cancer is the second most common gynecologic cancer in women and the leading cause of death caused by gynecologic malignancy. Surgery plays a…”
Get more information

Prognostic impact of marital status on survival of women with epithelial ovarian cancer by Mahdi, Haider, Kumar, Sanjeev, Munkarah, Adnan R., Abdalamir, Moshrik, Doherty, Mark, Swensen, Ron

“…Objectives The objective of this study is to examine the impact of marital status on survival of patients with epithelial ovarian cancer (EOC). Methods…”
Get full text

Cyclooxygenase (COX)-2 and Granulosa cell apoptosis in vitro by CAFFREY, Angela S, PATTON, William C, CORSELLI, Johannah U, SWENSEN, Ron E, KING, Alan, CHAN, Philip J

“…C-myc was studied in cyclooxygenase (COX)-2 associated granulosa cell apoptosis, Granulosa cells (N = 5 cases) were incubated for 24 h in either 1 or 50 microM…”
Get full text

Abstract POSTER-CTRL-1209: Ovarian cancer disparities in a high volume academic medical center by Hunt, Hayley, Rodriguez, Noah, Oda, Keiji, Wagner, Robert J., Swensen, Ron E.

“…Abstract Objective: To identify disparities in care and survival in ovarian cancer patients treated at a high volume academic center. Methods: A review of…”
Get full text

Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses by Liao, John Ben, Swensen, Ron E., Reichow, Jessica, Ovenell, Kelsie J, Childs, Jennifer, Higgins, Doreen, Buening, Barbara, Goff, Barbara Ann, Morishima, Chihiro, Disis, Mary L.

“…Abstract only…”
Get full text

Final results of a phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer by Swensen, Ron E., Goff, Barbara Ann, Childs, Jennifer, Higgins, Doreen, Gooley, Theodore, Fintak, Patricia A, Buening, Barbara, Disis, Mary L.

“…Abstract only 5082^ Background: Ovarian cancer patients with an anti-tumor immune response have a prolonged survival, suggesting that augmenting anti-tumor…”
Get full text